Suppliers and packagers for generic pharmaceutical drug: METHACHOLINE CHLORIDE

METHACHOLINE CHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193	NDA	Methapharm Inc.	64281-100-06	6 VIAL, GLASS in 1 BOX (64281-100-06) / 100 mg in 1 VIAL, GLASS (64281-100-00)	2013-03-27
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193	NDA	Methapharm Inc.	64281-110-06	6 PACKAGE in 1 PACKAGE (64281-110-06) / 6 CARTON in 1 PACKAGE (64281-110-05) / 1 KIT in 1 CARTON * 1 VIAL, PLASTIC in 1 KIT / 3 mL in 1 VIAL, PLASTIC (64281-113-00) * 1 VIAL, PLASTIC in 1 KIT / 3 mL in 1 VIAL, PLASTIC (64281-115-00) * 1 VIAL, PLASTIC in 1 KIT / 3 mL in 1 VIAL, PLASTIC (64281-114-00) * 1 VIAL, PLASTIC in 1 KIT / 3 mL in 1 VIAL, PLASTIC (64281-116-00) * 1 VIAL, PLASTIC in 1 KIT / 3 mL in 1 VIAL, PLASTIC (64281-112-00) * 1 VIAL, PLASTIC in 1 KIT / 3 mL in 1 VIAL, PLASTIC (64281-111-00)	2022-03-03

Methacholine Chloride Suppliers: Global Manufacturing and Regulatory Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for methacholine chloride, a muscarinic cholinergic agonist used primarily in diagnostic testing for asthma and airway hyperresponsiveness. It identifies key manufacturers, examines production capacities, and outlines the regulatory environment governing its availability.

What is Methacholine Chloride?

Methacholine chloride (CAS No. 61-72-3) is a synthetic ester of methacholine, a parasympathomimetic amine. It acts as a non-selective muscarinic receptor agonist. In pharmaceutical applications, it is exclusively formulated as a challenge agent for pulmonary function testing, administered via inhalation to assess bronchial reactivity. The standard diagnostic test involves administering increasing doses of inhaled methacholine chloride to determine the provocative concentration at which a significant decline in forced expiratory volume in one second (FEV1) occurs. This diagnostic tool is crucial for identifying and characterizing asthma, particularly in individuals with normal baseline spirometry but suspected airway hyperresponsiveness.

Global Manufacturing Landscape

The production of methacholine chloride is concentrated among a limited number of specialized chemical manufacturers. These companies often possess expertise in synthesizing fine chemicals and active pharmaceutical ingredients (APIs) under stringent quality controls. Production requires adherence to Good Manufacturing Practices (GMP) to ensure product purity, consistency, and safety for diagnostic use.

The primary manufacturing regions are North America and Europe, with a growing presence in Asia, particularly India, which has emerged as a significant hub for API production. The scale of production is generally moderate, catering to the niche market for diagnostic reagents rather than mass-market pharmaceuticals.

Key suppliers and their general operational scope include:

• Bachem AG (Switzerland): A leading global manufacturer of custom peptides and fine chemicals. Bachem supplies APIs for various therapeutic areas and diagnostic agents, including methacholine chloride, adhering to rigorous GMP standards. Their production capacity is geared towards high-purity, specialized chemicals.
• Hospira, Inc. (USA) - now part of Pfizer: Historically, Hospira was a significant producer of injectable pharmaceuticals and APIs. While specific current production of methacholine chloride by Pfizer's legacy Hospira division is not publicly detailed, their past involvement highlights the role of established pharmaceutical ingredient manufacturers in the supply chain. Pfizer's broader API capabilities suggest potential for continued or re-engaged production if market demand warrants.
• AMRI (Albany Molecular Research, Inc.) (USA): A contract development and manufacturing organization (CDMO) with extensive experience in API synthesis. AMRI provides services from early-stage development to commercial manufacturing. Their capabilities include complex organic synthesis and GMP production, making them a potential supplier for methacholine chloride.
• Various Indian API Manufacturers: Numerous Indian pharmaceutical companies specialize in the production of generic APIs. While specific companies manufacturing methacholine chloride are not always prominently advertised, entities with strong capabilities in small molecule synthesis and export under international regulatory standards are likely participants. Examples of companies with broad API portfolios that could include methacholine chloride production include Divi's Laboratories and Laurus Labs, though direct confirmation of methacholine chloride production requires specific inquiry. These manufacturers leverage cost efficiencies and a skilled workforce to serve global markets.

Production volumes are typically tied to the demand for diagnostic kits and the prevalence of asthma and related respiratory conditions requiring bronchial provocation testing. Unlike high-volume APIs for chronic disease management, methacholine chloride production is characterized by batch manufacturing with careful quality control for each lot.

Production Specifications and Quality Control

Methacholine chloride used in pharmaceutical diagnostics must meet exacting specifications to ensure patient safety and test accuracy. Key specifications typically include:

• Purity: Minimum purity levels are generally above 98%, often exceeding 99%. Impurities must be identified and quantified, with strict limits set for potentially toxic byproducts or substances that could interfere with the diagnostic assay.
• Identity: Confirmed through spectroscopic methods such as Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy, and Mass Spectrometry (MS).
• Assay: Quantitative determination of methacholine chloride content, typically performed using High-Performance Liquid Chromatography (HPLC).
• Water Content: Controlled to prevent degradation and ensure stability, often measured by Karl Fischer titration.
• Residual Solvents: Limits are set for residual organic solvents used during synthesis, in accordance with International Council for Harmonisation (ICH) guidelines.
• Heavy Metals: Tested to ensure levels are below regulatory thresholds.
• Microbial Limits: For sterile formulations, though the API itself may have limits on microbial contamination before sterile processing.

Quality control processes involve rigorous in-process testing and final product release testing. Manufacturers must maintain comprehensive documentation, including Certificates of Analysis (CoA) for each batch, detailing the results of all specified tests.

Regulatory Framework and Compliance

The supply of methacholine chloride for pharmaceutical use is governed by strict regulatory requirements enforced by health authorities worldwide.

Key Regulatory Bodies and Guidelines:

• U.S. Food and Drug Administration (FDA): Methacholine chloride used in diagnostic products is regulated as a drug. Manufacturers supplying to the U.S. market must comply with FDA's Current Good Manufacturing Practices (cGMP) outlined in 21 CFR Parts 210 and 211. Facilities are subject to FDA inspection.
• European Medicines Agency (EMA): In the European Union, APIs must comply with EudraLex Volume 4, the EU Guidelines for Good Manufacturing Practice. Manufacturers must be registered and inspected by national competent authorities within EU member states.
• International Council for Harmonisation (ICH): ICH guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), provide a harmonized framework for API manufacturing and quality management, adopted by regulatory authorities in many countries.
• National Regulatory Authorities: Other countries have their own regulatory bodies (e.g., Health Canada, Therapeutic Goods Administration (TGA) in Australia, Pharmaceuticals and Medical Devices Agency (PMDA) in Japan) with similar GMP requirements.

Drug Master Files (DMFs): API manufacturers often file Drug Master Files (DMFs) with regulatory agencies like the FDA. A DMF is a submission to the agency that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their marketing applications without having direct access to the proprietary information contained within.

Key Considerations for Suppliers:

• GMP Compliance: Demonstrable adherence to GMP standards is non-negotiable for supplying to regulated markets. This includes robust quality management systems, validated manufacturing processes, comprehensive documentation, and qualified personnel.
• Supply Chain Traceability: The ability to trace raw materials and finished products throughout the supply chain is essential.
• Regulatory Filings: Proactive engagement with regulatory agencies and maintenance of up-to-date DMFs or equivalent documentation is critical.
• Audits: Suppliers must be prepared for audits from prospective and existing customers, as well as regulatory inspections.

The regulatory landscape ensures that methacholine chloride used in medical diagnostics is of sufficient quality and purity to be safe and effective for its intended use. Non-compliance can lead to significant disruptions in supply and market access.

Market Dynamics and Supply Chain Considerations

The market for methacholine chloride is relatively stable but sensitive to demand fluctuations in diagnostic testing.

Factors Influencing Demand:

• Prevalence of Asthma and COPD: Increasing rates of respiratory diseases globally drive demand for diagnostic tools.
• Pulmonary Function Testing Guidelines: Recommendations from professional medical organizations for bronchial provocation testing influence utilization.
• Healthcare Infrastructure: Availability and accessibility of pulmonary function testing equipment and trained personnel.
• COVID-19 Impact: While the pandemic initially disrupted elective procedures, the long-term implications for respiratory health diagnostics are still unfolding, potentially increasing focus on airway reactivity assessment.

Supply Chain Vulnerabilities and Resilience:

• Limited Number of Manufacturers: A concentrated supply base can create vulnerability if one or more key suppliers face production issues, regulatory challenges, or geopolitical disruptions.
• Raw Material Sourcing: The synthesis of methacholine chloride relies on specific chemical precursors. Disruptions in the supply of these raw materials can impact production.
• Geopolitical Risks: Dependence on specific geographic regions for manufacturing can expose the supply chain to trade disputes, political instability, or natural disasters.
• Lead Times: For specialized APIs like methacholine chloride, lead times can be significant, requiring proactive inventory management and forecasting by diagnostic product manufacturers.

Strategies for Supply Chain Resilience:

• Dual Sourcing: Establishing relationships with multiple qualified suppliers can mitigate risks associated with single-source dependency.
• Inventory Management: Maintaining appropriate safety stock levels of both API and finished diagnostic products.
• Supplier Audits and Relationship Management: Regular assessment of supplier capabilities and fostering strong partnerships to ensure continuity.
• Geographic Diversification: Where feasible, sourcing from manufacturers in different geographic regions can reduce exposure to localized disruptions.
• Long-Term Contracts: Securing supply through long-term agreements can provide price stability and guaranteed availability.

The commercial availability of methacholine chloride is typically in the form of bulk API powder, which is then formulated by diagnostic kit manufacturers into inhalable solutions or dry powder formulations. These finished products are distributed to hospitals, clinics, and pulmonary function laboratories.

Key Takeaways

• Methacholine chloride is a critical API for asthma and airway hyperresponsiveness diagnostics, produced by a specialized segment of the fine chemical and API manufacturing industry.
• Global production is concentrated among a few manufacturers in North America, Europe, and increasingly Asia, with adherence to stringent GMP standards being paramount.
• Key suppliers are expected to meet high purity, identity, and quality specifications, supported by comprehensive regulatory documentation such as Drug Master Files.
• The supply chain, while stable, faces potential vulnerabilities due to the limited number of manufacturers and reliance on specific raw materials and regions.
• Regulatory compliance, particularly GMP, is a prerequisite for market access, with significant oversight from agencies like the FDA and EMA.

Frequently Asked Questions

1. What are the primary applications of methacholine chloride? Methacholine chloride is exclusively used as a diagnostic agent for assessing bronchial reactivity in patients suspected of having asthma or other conditions causing airway hyperresponsiveness. It is administered via inhalation during pulmonary function tests.

2. Who are the main regulatory bodies overseeing methacholine chloride production and supply? Key regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national competent authorities within other countries. Compliance with International Council for Harmonisation (ICH) guidelines, particularly ICH Q7 for APIs, is also critical.

3. What are the typical quality specifications for pharmaceutical-grade methacholine chloride? Pharmaceutical-grade methacholine chloride must meet high purity standards (typically >98%), with controlled levels of impurities, residual solvents, and heavy metals. Identity is confirmed through spectroscopic methods, and assay is performed via HPLC, all documented on a Certificate of Analysis.

4. What risks exist in the methacholine chloride supply chain, and how can they be mitigated? Risks include the limited number of manufacturers, raw material sourcing disruptions, and geopolitical factors. Mitigation strategies involve dual sourcing, maintaining safety stock inventories, conducting regular supplier audits, and diversifying sourcing geographically where possible.

5. Are there alternative agents to methacholine chloride for bronchial provocation testing? Yes, other agents like histamine, adenosine monophosphate (AMP), and bradykinin can also be used for bronchial provocation testing, although methacholine chloride remains a widely accepted standard due to its efficacy and well-established protocol.

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packaging, or Holding of Drugs; General. Retrieved from [FDA website] [2] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from [FDA website] [3] European Medicines Agency. (2010). EudraLex Volume 4 – EU Guidelines for Good Manufacturing Practice. Retrieved from [EMA website] [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH website]